Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Published Time:
2024-10-23 17:49
Source:
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
Following its inclusion in the 2022 list, Jiangsu Vcare's reappearance in 2024 reflects the industry's full recognition of its innovation strength. Since inception, Jiangsu Vcare has prioritized innovation as its core driver, continuously advancing technological transformation. In recent years, the company has significantly increased R&D investment, recruited top talent, and procured internationally advanced equipment, demonstrating unwavering commitment to innovation.
Jiangsu Vcare has established cutting-edge technology platforms—including AI molecular generation, drug screening, crystal/salt form selection, and novel formulations—focusing precisely on therapeutic areas such as cardiovascular, oncology, inflammation, and autoimmune diseases. Currently, it has5 clinical-stage Class I innovative drug projectsand over10 preclinical projectsunder development, forming a diversified, high-potential R&D pipeline.
Moving forward, Jiangsu Vcare will adhere to its innovation-driven and globalized strategy, targeting frontier technologies and unmet clinical needs to develop breakthrough therapeutics, contributing "Vcare Power" to global health.
Related News
05
2024
/
01
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of ankylosing spondylitis (AS). Preliminary blinded analysis from the clinical trial demonstrated favorable efficacy and safety profiles for VC005.
View Details
04
2024
/
01
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.
View Details
03
2024
/
01
Jiangsu Vcare Submitted an NDA for Anti- platelet Drug Vicagrel to the US
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) submitted an NDA to the US FDA for Vicagrel capsules for the treatment of acute coronary syndrome (ACS), ischemic stroke, and confirmed peripheral arterial disease. This marks the first NDA submission from Jiangsu Vcare's innovative drug pipeline, representing a significant milestone.
View Details
02
2024
/
01
Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment.
View Details
13
2023
/
12
Jiangsu Vcare Approved to Establish "Provincial-Level Enterprise Technology Center"
Recently, the Jiangsu Provincial Department of Industry and Information Technology released the list of enterprises proposed for recognition as 2023 Provincial-Level Enterprise Technology Centers. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) has been recognized as a"2023 Provincial-Level Enterprise Technology Center".
View Details
10
2023
/
11
Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial
Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn